Physician profile
Steven Delee
NPI 1407845001
$9,868.81
in general payments reported to CMS, 2019-2025
57 companies · $948 in 2025
The $948 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,972 · 2020: $1,442 · 2021: $1,802 · 2022: $292 · 2023: $1,583 · 2024: $1,829 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,140 · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,139.72 |
| Education | $220.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,190.84 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,040.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $893.67 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $694.08 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $593.45 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Teva Pharmaceuticals USA, INC. | $468.48 | 2019-2025 | Austedo Xr, Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $385.87 | 2019-2024 | Xifaxan |
| Lilly USA, LLC | $326.36 | 2019-2025 | Jardiance, Trulicity, Mounjaro |
| Amgen INC. | $276.61 | 2019-2025 | Otezla, Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $196.83 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.81 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $170.26 | 2019-2023 | |
| Ironshore Pharmaceuticals INC. | $146.56 | 2019-2024 | Jornay Pm |
| Allergan, INC. | $142.34 | 2019-2020 | |
| Astellas Pharma US INC | $134.51 | 2019-2024 | Veozah |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Delee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.